TPI [TIANYIN PHARMACEUTICAL] 25-NSE: (Original Filing)

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;} .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;} .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;} .FormNumText {font-size: small; font-weight: bold; font-family:] []

By | 2016-05-19T04:08:19+00:00 May 18th, 2016|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 25-NSE: .FormData {color: blue; background-color: white; font-size: small; font-family:

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif;} .FormDataC {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: center;} .FormDataR {color: blue; background-color: white; font-size: small; font-family: Times, serif; text-align: right;} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif;} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif;} .FormNumText {font-size: small; font-weight: bold; font-family:] []

By | 2016-05-19T04:09:05+00:00 May 18th, 2016|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] NT 10-Q: (Original Filing)

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: March 31, 2016 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By | 2016-05-17T03:49:39+00:00 May 16th, 2016|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] NT 10-Q: FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER:

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: March 31, 2016 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By | 2016-05-17T03:50:36+00:00 May 16th, 2016|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMA] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) ☒ March 31, 2016 For the quarterly period ended ☐ For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 16, 2016 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 ex321.htm]

By | 2016-05-17T03:52:54+00:00 May 16th, 2016|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMA] 10-Q: FORM 10-Q (Mark One) ☒ March 31, 2016

[FORM 10-Q (Mark One) ☒ March 31, 2016 For the quarterly period ended ☐ For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: May 16, 2016 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 ex321.htm]

By | 2016-05-17T03:53:51+00:00 May 16th, 2016|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)

[CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT April 29, 2016 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28- 8551-6696 ☐ ☐]

By | 2016-05-07T22:12:06+00:00 May 5th, 2016|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 8-K: CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM

[CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT April 29, 2016 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28- 8551-6696 ☐ ☐]

By | 2016-05-07T22:13:55+00:00 May 5th, 2016|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments
Skip to toolbar